Floatz logo

Alpha-Interferon

Chronic Myeloproliferative Disorders

National Cancer Institute (NCI)Phase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

80 Active assets in the Chronic Myeloproliferative Disorders cohort.

Asset / SponsorPhaseRating
Evomela
Center for International Blood and Marrow Transplant Research
Phase 2/3BBB
Fludarabine
Sawa Ito, MD
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Busulphan
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
kidney cancerDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →